PA
RVNC

Profund Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Profund Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,710
Closed -$112K – 1185
2024
Q1 		$112K Sell
22,710
-15,882
-41% -$94K ﹤0.01% 1121
2023
Q4 		$339K Buy
38,592
+3,631
+10% +$29.7K 0.01% 719
2023
Q3 		$401K Buy
34,961
+16,355
+88% +$314K 0.02% 532
2023
Q2 		$471K Buy
18,606
+1,585
+9% +$49.4K 0.03% 533
2023
Q1 		$548K Buy
+17,021
New +$531K 0.03% 479
2021
Q3 		– Sell
-6,944
Closed -$205K – 1459
2021
Q2 		$205K Buy
+6,944
New +$200K 0.01% 1345
2018
Q4 		– Sell
-11,144
Closed -$277K – 1459
2018
Q3 		$277K Buy
+11,144
New +$303K 0.01% 1250

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Profund Advisors's RVNC Position: Q2 2024 in Review

Profund Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 22,710 shares — an estimated $112K sold.

Profund Advisors first reported a position in RVNC in Q3 2018 and held it in 7 quarters. The position peaked at $548K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • Profund Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • Profund Advisors sold 22,710 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $112K.
  • Profund Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2018 and held it in 7 quarters.
  • Profund Advisors's Revance Therapeutics, Inc. position peaked at $548K in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Profund Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.